Frequent Mistakes to Avoid When Designing Feasibility Surveys

Why Survey Design Matters in Clinical Feasibility

Feasibility surveys are the first checkpoint in clinical trial execution. Sponsors, CROs, and clinical teams rely on these tools to determine which investigator sites are capable of enrolling, complying, and delivering high-quality data. However, flawed survey design can compromise this entire process—leading to site underperformance, protocol deviations, missed enrollment targets, and costly delays. Regulatory authorities like the FDA and EMA have highlighted the importance of accurate feasibility assessments in multiple inspection reports.

Designing an effective feasibility questionnaire is not just about gathering information—it’s about ensuring the **quality, clarity, and relevance** of the data collected. Poor design choices can introduce bias, reduce response rates, and provide misleading inputs, ultimately affecting trial success.

This article explores common pitfalls in feasibility survey design and provides corrective strategies to improve accuracy, efficiency, and regulatory alignment.

1. Over-Reliance on Generic Questionnaires

One of the most frequent mistakes is using generic, one-size-fits-all surveys across all therapeutic areas and trial phases. This ignores the unique requirements of different indications. For example, asking only “Do you have imaging capabilities?” in an oncology trial overlooks critical aspects like:

• Type of imaging (CT, MRI, PET)
• RECIST or iRECIST measurement familiarity
• Archiving and transfer compliance (DICOM format)

Similarly, a vaccine trial might need cold chain logistics and mass-screening capacity questions, which may be completely irrelevant to a rare disease gene therapy study. Lack of customization can cause misaligned expectations and downstream failures.

2. Ambiguous or Leading Questions

Vague phrasing leads to inconsistent interpretation and invalid data. For instance, asking “Can you enroll patients quickly?” is subjective. What qualifies as “quick” for one site may differ from another. Instead, a better version would be:

“How many patients fitting the protocol inclusion criteria did your site enroll in the last 12 months for similar Phase II studies?”

Leading questions also bias the respondent. “You have successfully conducted previous trials, correct?” might trigger social desirability bias. Neutral, fact-based phrasing is key.

3. Excessive Length and Complexity

Lengthy surveys with poor flow reduce completion rates and frustrate site staff. In multi-center trials, sites often have limited staff availability, especially during active study periods. Surveys that take over 45 minutes are less likely to be completed accurately. Issues include:

• Redundant questions across sections
• Poor section organization (e.g., mixing regulatory and infrastructure questions)
• Lack of autosave or ability to pause and resume digital forms

As a best practice, limit questionnaires to 25–30 well-structured questions for initial feasibility, followed by site-specific deep dives as needed. Use digital platforms that allow intuitive navigation and validation.

4. Lack of Data Validation or Documentation Fields

Another flaw is the absence of cross-checks or request for supporting documentation. For example, if a site claims it can enroll 100 patients over 6 months, sponsors should request either:

• Patient registry screenshots
• De-identified electronic health record reports
• Recruitment logs from similar studies

Without these, responses are based solely on memory or estimates, increasing risk of over-promising. Platforms should include fields for file uploads, comment boxes for clarification, and warning prompts for unusual entries.

5. Ignoring Historical Site Performance Data

Failing to consider a site’s previous trial history is a major oversight. Historical data helps contextualize feasibility answers and filter out consistently underperforming sites. For example:

Integrating such data-driven benchmarking within the survey design significantly improves reliability and transparency.

Transition to Solutions and Best Practices

Now that we’ve identified major pitfalls in feasibility survey design, the next part will offer regulatory-aligned solutions, practical templates, and technology integrations to improve the quality of your feasibility assessments.

6. Neglecting to Capture PI and Sub-Investigator Details

Many feasibility surveys focus primarily on site-level infrastructure while ignoring investigator qualifications. Yet, the PI’s past experience, availability, and regulatory track record are critical success factors. A well-designed survey should capture:

• Number of trials conducted in the last 5 years
• Therapeutic area alignment with the protocol
• GCP training validity and inspection history
• Ratio of PI to concurrent active trials

Neglecting to gather such details could lead to site activation delays due to regulatory rejection of PI credentials or unavailability.

7. Overlooking Regional and Regulatory Context

Global feasibility surveys often ignore country-specific regulations and operational limitations. For example:

• In India, the CDSCO has specific rules regarding ethics approvals and compensation
• In Japan, feasibility surveys must include PMDA-specific compliance sections
• In the EU, surveys must align with EU Clinical Trial Regulation (CTR) timelines and document requirements

Not including such country-specific sections can result in inaccurate site feasibility outcomes. For global trials, it’s critical to tailor questions by region or include branching logic that triggers local regulatory queries based on country selection.

8. No Mechanism to Capture Feasibility Risk Flags

A robust feasibility survey should include logic or scoring that auto-generates red flags based on site responses. For instance:

Response	Flag
PI is involved in 7 concurrent studies	Investigator overload
Site has no GCP training in last 3 years	Non-compliance risk
Startup timeline > 90 days	High activation risk

Such automated risk indicators help feasibility managers prioritize follow-ups and site visits.

9. Lack of Digital Integration and Data Traceability

Paper-based or email surveys still exist in some trials, resulting in data loss, miscommunication, and lack of audit trails. Regulatory inspectors, including from the FDA, expect version control, date/time stamps, and investigator signatures on feasibility forms.

Surveys should be integrated into platforms like Veeva CTMS, Clario Feasibility, or other compliant digital tools. This enables audit-ready documentation and seamless comparison across protocols and regions.

10. Ignoring Site Feedback for Continuous Improvement

Finally, many sponsors and CROs fail to review site feedback post-survey. Sites may provide comments such as:

• “Questions are repetitive or unclear”
• “Form is too long for busy clinics”
• “Unable to attach required documents easily”

Incorporating this feedback into subsequent versions ensures higher response rates, better data, and improved sponsor-site collaboration. Sponsors should conduct post-survey reviews or pilot testing to optimize forms continuously.

Best Practice Recommendations

• Limit initial surveys to 25–30 critical questions
• Use digital tools with conditional logic and data upload fields
• Benchmark recruitment estimates with historical performance
• Customize by therapeutic area and regulatory region
• Include risk scoring and auto-flagging mechanisms
• Maintain an audit-ready record with version control and timestamps

Tools like Clinscape, TrialHub, and Medidata can help structure and automate these best practices into scalable survey systems.

Conclusion

Feasibility surveys are the foundation of successful clinical trials. Yet, poor design introduces risk, waste, and non-compliance. Sponsors and CROs must recognize and avoid the common pitfalls outlined above—generic questions, ambiguous wording, missing validations, and absence of risk flagging. By adopting best practices, leveraging digital platforms, and integrating historical data, sponsors can build robust, regulatory-aligned feasibility tools that drive accurate site selection and successful trial execution.

Adapting Feasibility Tools to Specific Therapeutic Areas in Clinical Trials

Why Customization Matters in Feasibility Assessments

While feasibility questionnaires are a standard component of clinical trial planning, a “one-size-fits-all” approach often results in incomplete or misleading data. Different therapeutic areas present unique operational, regulatory, and recruitment challenges. Therefore, it is essential to adapt feasibility tools based on the specific clinical, procedural, and patient population characteristics of each therapeutic indication.

Regulatory agencies like the FDA and EMA expect feasibility efforts to align with study-specific complexities. For example, a Phase III oncology trial will have very different infrastructure and recruitment requirements compared to a vaccine study or a dermatology trial. Customization ensures that the sponsor gathers high-fidelity, indication-specific data, which reduces trial delays, improves protocol adherence, and enhances inspection readiness.

In this tutorial, we explore how sponsors and CROs can develop and deploy feasibility tools tailored to therapeutic areas including oncology, cardiology, infectious diseases, CNS disorders, and rare diseases.

Key Variables Differentiating Therapeutic Areas

Each therapeutic area involves unique variables that influence trial feasibility, including:

• Diagnostic criteria and screening processes
• Specialized equipment and lab tests
• Patient population size and disease prevalence
• Eligibility complexity and inclusion/exclusion criteria
• Site specialization and investigator qualifications

For example, an oncology trial may require immunohistochemistry, genetic sequencing, and radiologic assessments, while a vaccine trial may emphasize storage conditions for biologics and capacity for large-scale subject screening. Failing to account for these differences can lead to underperformance and protocol deviations.

Customizing Feasibility Tools in Oncology Trials

Oncology trials are often complex, with multiple arms, biomarker-based eligibility, and long treatment durations. Therefore, feasibility tools must address:

• Availability of tissue samples for biomarker testing
• Access to imaging facilities for RECIST-based assessments
• Experience in handling cytotoxic agents and managing SAE reporting
• Supportive care services like transfusion, nutrition, and palliative care

Below is a sample customization framework for oncology feasibility:

Oncology sites must also demonstrate access to multidisciplinary tumor boards, availability of radiology archiving systems, and electronic SAE tracking tools such as Argus Safety. To cross-reference recruitment and prior site experience, sponsors may consult the EU Clinical Trials Register.

Adapting Feasibility for Cardiovascular Trials

Cardiology studies may involve device implantation, ECG monitoring, and stress testing. In such cases, feasibility tools must capture:

• Availability of validated ECG and echocardiogram equipment
• GCP training in cardiovascular endpoints (e.g., MACE criteria)
• Presence of a catheterization lab or interventional cardiologist
• Patient adherence history in hypertension or dyslipidemia trials

Sample values might include:

• Validated ECG machine model: GE MAC 5500
• Calibration certificate date: June 2025
• Cardiology sub-investigator GCP completion: March 2024

Moreover, cardiology trials may need precise documentation of concomitant medications and lifestyle interventions. Questionnaires must be adapted to capture these site competencies.

Feasibility Tools for Infectious Disease Trials

Infectious disease trials—especially in vaccines or antimicrobial resistance studies—require a different set of site capabilities. Sponsors must customize feasibility questionnaires to capture:

• Cold-chain infrastructure for biologics (2–8°C and -20°C storage)
• Experience with biosafety level (BSL-2 or BSL-3) laboratory handling
• Regulatory familiarity with expedited review processes (e.g., EUA)
• Access to outbreak-prone communities or travel clinics

Feasibility templates for such trials often include verification of:

Sites that have participated in past epidemic response trials (e.g., COVID-19, H1N1) often score higher in feasibility assessments due to institutional readiness and protocol familiarity.

Feasibility Considerations in CNS Trials

CNS trials for indications like Alzheimer’s, Parkinson’s, or depression bring unique recruitment and assessment challenges. Key customization points include:

• Site capability for neurocognitive assessments (e.g., MMSE, MoCA)
• Investigator training in psychiatric or neurologic scales
• Caregiver consent handling for dementia patients
• Experience with long-term follow-up visits (≥12 months)

Example question: “Is your site trained in administering ADAS-Cog or CDR-SB assessments for Alzheimer’s patients?”

Feasibility tools must also factor in patient adherence barriers, comorbidities, and ability to comply with imaging and lab visit schedules. CNS studies often suffer from high dropout rates, so feasibility assessments should include questions on patient retention strategies.

Special Feasibility Approaches in Rare Disease Trials

Rare disease studies are constrained by extremely small patient populations. Feasibility tools in this context must go beyond traditional metrics and emphasize:

• Site access to patient registries or genetic databases
• Partnerships with advocacy groups or KOL networks
• Willingness to enroll non-local patients (e.g., travel support programs)
• Experience in adaptive trial designs and expanded access protocols

Due to ultra-orphan populations, sponsors may consider virtual or decentralized feasibility approaches, integrating telemedicine and remote monitoring tools. Additionally, feasibility questionnaires should include sections on protocol flexibility and site logistics for rare disease patients traveling long distances.

Best Practices for Implementing Customized Tools

To deploy customized feasibility tools effectively:

• Develop therapeutic area-specific templates reviewed by KOLs
• Pre-fill public domain data (e.g., IRB timelines) to reduce site burden
• Digitize questionnaires using secure platforms integrated with CTMS
• Score site responses using indication-weighted algorithms
• Train feasibility teams on therapeutic-specific nuances

Some organizations maintain a Feasibility SOP that includes annexures for oncology, cardiology, etc., ensuring consistency while allowing adaptation. For sponsors working with multiple CROs, standardizing customized tools via cross-functional working groups is recommended.

Conclusion

Feasibility tool customization is a regulatory, scientific, and operational imperative. Generic questionnaires can no longer capture the complexity of modern trials across diverse therapeutic areas. By developing indication-specific tools—grounded in real-world data, infrastructure requirements, and investigator qualifications—sponsors can enhance patient recruitment, ensure compliance, and minimize protocol deviations. With global trials becoming more complex, therapeutic customization of feasibility tools is essential for success in today’s regulatory environment.

Strategies to Effectively Prepare for a Type B FDA Meeting

What Is a Type B Meeting and Why Is It Critical?

In the U.S. drug development process, structured communication with the Food and Drug Administration (FDA) is essential for aligning clinical, regulatory, and manufacturing strategies. Type B meetings are formal, scheduled interactions between sponsors and the FDA designed to address key development milestones, including Pre-IND meetings, End-of-Phase 2 meetings, and Pre-NDA/BLA meetings.

These meetings allow sponsors to clarify regulatory expectations, mitigate potential risks, and gain critical feedback before committing major resources to clinical trials or submission activities. Poor preparation, vague questions, or missing documents can derail the utility of the meeting and delay development timelines.

Sponsors also monitor global regulatory frameworks through platforms such as WHO ICTRP to understand precedents for similar meetings worldwide.

When to Request a Type B Meeting

The FDA recognizes the following as formal Type B meetings:

• Pre-IND Meeting: Before initial IND submission
• End-of-Phase 2 Meeting (EOP2): To discuss pivotal trial design
• Pre-NDA/BLA Meeting: To align on final submission strategy

These meetings are generally granted within 60 days of request, with meeting dates confirmed 21 days after FDA receives the initial request.

Preparing the Meeting Request

A successful FDA engagement starts with a clear and focused meeting request. This document should include:

• Purpose of the meeting and specific regulatory milestone
• Proposed agenda and list of discussion topics
• Draft questions to be addressed
• Preferred format (face-to-face, virtual, or written response)
• Brief background on the investigational product

Requests must be sent to the appropriate division electronically through the FDA’s CDER NextGen Portal or ESG.

Developing a High-Impact Briefing Package

The briefing package provides FDA reviewers with essential information to prepare for the meeting. It must be submitted no later than 30 days before the meeting and should include:

• Cover letter and executive summary
• Product overview, mechanism of action, and indication
• Clinical development history and status
• Nonclinical, CMC, and clinical data summaries
• Numbered, specific questions for FDA feedback

Sample Table: Draft Questions for a Type B Meeting

Execution, Documentation, and Post-Meeting Actions

Internal Preparation and Role Assignments

A well-coordinated internal preparation plan can make or break a Type B meeting. Sponsors should assign clear roles:

• Regulatory Lead: Owns the meeting agenda and communication with the FDA
• Clinical Lead: Responds to questions on trial design and endpoints
• CMC Lead: Addresses manufacturing, stability, and product quality queries
• Medical Monitor: Handles safety and adverse event strategy

Conduct a mock meeting or rehearsal to anticipate possible FDA follow-up questions, especially for End-of-Phase 2 meetings.

Conducting the Meeting: What to Expect

Type B meetings are typically 1 hour long and held via teleconference. The FDA project manager will lead the session, and FDA reviewers from relevant disciplines will participate.

Key tips:

• Stick to the agenda — time is limited
• Do not present lengthy slides unless requested
• Clarify ambiguities without debating FDA positions
• Take detailed notes and confirm FDA statements post-meeting

FDA Meeting Minutes and Their Importance

The FDA will issue official meeting minutes within 30 calendar days. These minutes are binding and should reflect the meeting’s discussions and conclusions accurately.

Sponsors should review the draft minutes carefully and request corrections within 7 calendar days if discrepancies exist.

Post-Meeting Actions and Alignment

After the meeting:

• Circulate minutes internally to align all stakeholders
• Document all decisions and rationale in the regulatory strategy file
• Update protocols, CMC plans, or timelines as agreed upon
• Prepare for follow-up meetings if further guidance is needed

All commitments and clarifications should be traceable in the IND submission history and eCTD sequence.

Global Variations in Regulatory Engagement

While the FDA’s Type B meeting structure is well-defined, other regulatory agencies offer similar scientific advice or pre-submission meetings:

• EMA: Scientific Advice Procedures
• PMDA (Japan): Clinical Trial Consultation
• TGA (Australia): Pre-submission meetings for clinical trial applications

Regulatory teams should align global development plans with feedback from multiple authorities to ensure harmonization.

Conclusion: Maximizing Value from Your Type B FDA Meeting

A Type B meeting with the FDA is a powerful regulatory milestone that can accelerate drug development, clarify expectations, and de-risk clinical programs. Success depends on strategic planning, precision in communication, and structured documentation.

By crafting a focused agenda, asking high-value questions, and aligning internally, sponsors can turn FDA meetings into catalysts for forward momentum. Thorough meeting preparation is not just best practice — it’s a regulatory imperative.

Preparing for a Successful Pre-IND Meeting with the FDA

Introduction to Pre-IND Meetings

A Pre-Investigational New Drug (Pre-IND) meeting is one of the most valuable opportunities for sponsors to engage with the FDA early in the drug development process. Classified as a Type B meeting, it enables sponsors to align their nonclinical, clinical, and Chemistry, Manufacturing, and Controls (CMC) plans with FDA expectations before submitting an IND application.

The objective is to de-risk the IND submission by obtaining feedback on data gaps, clinical protocol design, and regulatory concerns. While Pre-IND meetings are not mandatory, they are strongly encouraged—especially for novel molecules, complex products, or first-in-human (FIH) studies.

Regulatory professionals frequently consult international regulatory portals such as India’s Clinical Trials Registry (CTRI) to understand how similar investigational products were planned and approved.

When Should You Request a Pre-IND Meeting?

Sponsors typically request a Pre-IND meeting 6–12 months prior to submitting their IND. This timing allows enough flexibility to:

• Incorporate FDA feedback into the development plan
• Complete additional nonclinical studies if required
• Revise the clinical protocol or CMC data

The ideal timing depends on your program’s complexity. For high-risk drugs such as gene therapies or cytotoxic agents, early interaction is critical.

Requesting the Meeting: Key Requirements

Sponsors must submit a formal meeting request to the appropriate FDA division. The request should include:

• Proposed meeting format (teleconference, written response, or face-to-face)
• Rationale for the meeting
• A list of proposed questions
• Timeline of development activities

The FDA typically responds within 21 calendar days, confirming whether the meeting is granted and specifying the date (usually 60 days from acceptance).

Preparing the Briefing Package

The briefing package is the foundation of the meeting and must be submitted no later than 30 days before the scheduled meeting. It must be clear, concise, and structured to enable efficient FDA review.

The standard contents of a briefing package include:

• Executive Summary
• Product description and mechanism of action
• Summary of completed and planned nonclinical studies
• Overview of CMC, including formulation and stability data
• Draft clinical protocol or study synopsis
• Specific, numbered questions for FDA input

Sample Table: Pre-IND Questions Format

Strategic Tips for an Effective Pre-IND Meeting

Simply securing a Pre-IND meeting isn’t enough — the goal is to extract meaningful feedback. Consider these best practices:

• Prioritize high-impact questions over low-value administrative ones
• Use cross-functional teams to prepare answers to anticipated FDA queries
• Keep briefing documents under 100 pages, unless justified
• Use standard CTD module formats for ease of review

Meeting Execution and Post-Meeting Actions

Conducting the Meeting: Roles and Responsibilities

Pre-IND meetings are typically held as teleconferences. The meeting is led by the FDA project manager, and attendees may include nonclinical, clinical, and CMC reviewers.

The sponsor team should include a regulatory lead, subject matter experts, and a designated note-taker. Key roles include:

• Regulatory Lead: Drives agenda and manages time
• Clinical Lead: Answers protocol-related questions
• CMC Lead: Addresses manufacturing and formulation queries

The sponsor should rehearse the meeting in advance, including potential follow-up questions. It’s also wise to prepare contingency slides or data to address unanticipated concerns.

FDA Responses: Interpreting and Using the Feedback

The FDA will issue official meeting minutes within 30 days, which become part of the regulatory record. These minutes will reflect:

• The FDA’s responses to each submitted question
• Clarifications or follow-ups discussed during the meeting
• Agreements or disagreements on trial design and data plans

Sponsors should not assume verbal comments override written responses. Regulatory actions must be based on documented FDA positions.

Addressing Gaps and Follow-Up Actions

Based on the meeting outcomes, sponsors may need to:

• Conduct additional safety studies
• Revise the clinical protocol or dosing plan
• Update CMC controls or release specifications

For instance, if the FDA recommends a lower starting dose, the sponsor should update the protocol and justify changes in the IND cover letter.

Integrating Pre-IND Feedback into the IND Package

Incorporating FDA feedback improves the quality and reviewability of the final IND. When submitting the IND, sponsors should include a section summarizing how each Pre-IND comment was addressed.

This shows responsiveness, regulatory maturity, and risk-based thinking — key values that FDA reviewers appreciate. It may also reduce the likelihood of a clinical hold.

Global Perspective: Similar Meetings in Other Jurisdictions

Many countries have equivalent mechanisms for early regulatory interaction. Examples include:

• EU (EMA): Scientific Advice Meeting
• Japan (PMDA): Consultation Meetings
• Canada (Health Canada): Pre-CTA Meetings

These processes vary in formality but serve the same purpose — aligning on data expectations and minimizing regulatory risk.

For comparative insights, sponsors may consult databases like ANZCTR (Australia & New Zealand Clinical Trials Registry).

Conclusion: Leveraging the Pre-IND Meeting for Regulatory Success

A Pre-IND meeting is more than a procedural step — it is a strategic engagement that can shape the trajectory of a drug development program. Thoughtfully preparing the briefing package, asking the right questions, and fully leveraging FDA insights can significantly improve IND quality and reduce review timelines.

Sponsors should treat the Pre-IND meeting as an opportunity to demonstrate scientific readiness, regulatory diligence, and commitment to patient safety. When executed correctly, this meeting becomes a foundational moment in successful IND planning and clinical trial authorization.